Search

Your search keyword '"Setnicka A"' showing total 114 results
Start Over Author "Setnicka A"
114 results on '"Setnicka A"'

19. Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease

Author

Chalupova, Katarina, Korabecny, Jan, Bartolini, Manuela, Monti, Barbara, Lamba, Doriano, Caliandro, Rosanna, Pesaresi, Alessandro, Brazzolotto, Xavier, Gastellier, Anne-Julie, Nachon, Florian, Pejchal, Jaroslav, Jarosova, Michaela, Hepnarova, Vendula, Jun, Daniel, Hrabinova, Martina, Dolezal, Rafael, Zdarova Karasova, Jana, Mzik, Martin, Kristofikova, Zdena, Misik, Jan, Muckova, Lubica, Jost, Petr, Soukup, Ondrej, Benkova, Marketa, Setnicka, Vladimir, Habartova, Lucie, Chvojkova, Marketa, Kleteckova, Lenka, Vales, Karel, Mezeiova, Eva, Uliassi, Elisa, Valis, Martin, Nepovimova, Eugenie, Bolognesi, Maria Laura, and Kuca, Kamil

Published
2019
Full Text
View/download PDF

25. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models

Author

McCampbell, Alex, Cole, Tracy, Wegener, Amy J., Tomassy, Giulio S., Setnicka, Amy, Farley, Brandon J., Schoch, Kathleen M., Hoye, Mariah L., Shabsovich, Mark, Sun, Linhong, Luo, Yi, Zhang, Mingdi, Thankamony, Sai, Salzman, David W., Cudkowicz, Merit, Graham, Danielle L., Bennett, C. Frank, Kordasiewicz, Holly B., Swayze, Eric E., and Miller, Timothy M.

Subjects
Antisense drugs -- Research -- Health aspects -- Dosage and administration, Amyotrophic lateral sclerosis -- Genetic aspects -- Research -- Care and treatment, Gene mutation -- Research, Health care industry
Abstract

Mutations in superoxide dismutase 1 (SOD1) are responsible for 20% of familial ALS. Given the gain of toxic function in this dominantly inherited disease, lowering SOD1 mRNA and protein is predicted to provide therapeutic benefit. An early generation antisense oligonucleotide (ASO) targeting SOD1 was identified and tested in a phase I human clinical trial, based on modest protection in animal models of SOD1 ALS. Although the clinical trial provided encouraging safety data, the drug was not advanced because there was progress in designing other, more potent ASOs for CNS application. We have developed next- generation SOD1 ASOs that more potently reduce SOD1 mRNA and protein and extend survival by more than 50 days in [SOD1.sup.G93A] rats and by almost 40 days in [SOD1.sup.G93A] mice. We demonstrated that the initial loss of compound muscle action potential in [SOD1.sup.G93A] mice is reversed after a single dose of SOD1 ASO. Furthermore, increases in serum phospho-neurofilament heavy chain levels, a promising biomarker for ALS, are stopped by SOD1 ASO therapy. These results define a highly potent, new SOD1 ASO ready for human clinical trial and suggest that at least some components of muscle response can be reversed by therapy., Introduction Amyotrophic lateral sclerosis (ALS) is caused by the loss and dysfunction of neurons in motor pathways and leads to severe weakness, stiffness, and ultimately death in 3-5 years. Approximately [...]

Published
2018
Full Text
View/download PDF

44. Inducted axial chirality in the biphenyl core of the C(Super alpha)-tetrasubstituted alpha-amino acid residue Bip and subsequent propagation of chirality in (Bip)(Sub n)/Val oligopeptides

Author

Mazaleyrat, Jean-Paul, Wright, Karen, Gaucher, Anne, Toulemonde, Nathalie, Wakselman, Michel, Oancea, Simona, Peggion, Cristina, Formaggio, Fernando, Setnicka, Vladimir, Keiderling, Timothy A., and Toniolo, Claudio

Subjects
Oligopeptides -- Chemical properties, Glycine -- Chemical properties, Chirality -- Analysis, Chemistry
Abstract

In the dipeptides Boc-Bip-L-Val-OMe and Boc-Bip-D-Val-OMe, and induced axial chiralityh in the biphenyl core of the Bip residue, a conformationally labile, proatropoisomeric C(super alpha, alpha)-disubstituted glycine, is observed by electronic CD and 1H NMR. The findings show that the chiral induction is significantly higher when the Val residue is located at the C-terminal position of Bip.

Published
2004

45. (3R,4S)-4-(4-fluorophenyl)-3-hydroxymethyl-1-methylpiperidine: conformation and structure monitoring by vibrational circular dichroism

Author

Bour, Petr, Navratilova, Hana, Setnicka, Vladimir, Urbanova, Marie, and Volka, Karel

Subjects
Chemistry, Organic -- Research, Circular dichroism -- Analysis, Fluorine -- Physiological aspects, Molecules -- Analysis, Biological sciences, Chemistry
Abstract

Research has been conducted on the absorption and vibrational circular dichroism spectra of the (3R,4S)-4-(4-fluorophenyl)-3-hydroxymethyl-1-methylpiperidine. The measurements of these spectra have been analyzed in determining the compound's absolute configuration and conformations and the results are reported.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results